EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Short‐Term Risk Stratification in Alcohol‐Associated Hepatitis: Small HDL Particles and Inflammation Vulnerability Index Values Improve Model for End‐Stage Liver Disease

Eduardo Vilar-Gomez iD, Margery A Connelly iD, Vijay H Shah, Irina Shalaurova, Jill M Rafalko iD, Arun J Sanyal iD, Naga P Chalasani iD, Samer Gawrieh iD, TREAT Consortium

Alcohol, Clinical and Experimental Research · 2026

DOI: 10.1111/acer.70388 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alcohol, Clinical and Experimental Research, 2026. Verfasst von Eduardo Vilar-Gomez und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology & Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Inflammation, End Stage Liver Disease, Hepatitis, Alcoholic, Lipoproteins, HDL. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAAA NIH HHS, National Institute on Alcohol Abuse and Alcoholism.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Alcohol‐associated hepatitis (AH) has high short‐term mortality, whereas current prognostic models mainly reflect liver and renal dysfunction. The Metabolic Vulnerability Index (MVX) is a nuclear magnetic resonance‐derived score comprising the Inflammation Vulnerability Index (IVX; small high‐density lipoprotein particles [S‐HDL‐P] and GlycA) and the Metabolic Malnutrition Index (MMX). We evaluated whether MVX, IVX, and IVX components improve 90‐day mortality prediction beyond Model for End‐Stage Liver Disease (MELD) in AH.

Methods

Serum samples from 196 patients with AH, 169 heavy‐drinking controls, and 351 healthy controls were analyzed by nuclear magnetic resonance spectroscopy. The primary outcome was 90‐day AH‐related mortality. Biomarkers were modeled continuously after standardization within the AH cohort; S‐HDL‐P was modeled per 1 SD decrease. Cox models were adjusted for MELD, age, sex, white blood cell count, and baseline antibiotic or corticosteroid use. Model performance was assessed using Akaike information criterion (AIC), likelihood‐ratio testing, and Harrell's C ‐statistic.

Results

Among patients with AH, 30 AH‐related deaths occurred within 90 days (15.3%). IVX and MVX were highest in AH cases and increased with AH severity, whereas MMX did not consistently differentiate severity. Lower S‐HDL‐P was independently associated with 90‐day mortality in fully adjusted models (HR, 1.84; 95% CI, 1.01–3.35; p = 0.045), whereas GlycA was not (HR, 0.86; 95% CI, 0.54–1.37; p = 0.527). Adding S‐HDL‐P improved fully adjusted MELD‐based model fit (AIC, 298.97 vs. 301.46; LR p = 0.034; C ‐statistic, 0.741 vs. 0.729). IVX showed supportive improvement in model fit and discrimination (AIC, 299.81; LR p = 0.056; C ‐statistic, 0.749). Continuous MELD interaction analyses supported risk separation for S‐HDL‐P (LR χ 2 = 6.20; p = 0.045) and IVX (LR χ 2 = 6.64; p = 0.036).

Conclusions

Lower S‐HDL‐P appears to be the principal short‐term prognostic component within the IVX domain in AH. S‐HDL‐P and IVX may refine MELD‐based 90‐day risk stratification, pending external validation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

InflammationEnd Stage Liver DiseaseHepatitis, AlcoholicLipoproteins, HDLHumansFemaleMaleMiddle AgedAdultBiomarkersRisk AssessmentPrognosisAged

Stichwörter der Autor:innen

alcohol‐associated hepatitisinflammation vulnerability indexliver diseasemetabolic malnutritionnuclear magnetic resonance spectroscopyshort‐term mortality

Substanzen

Lipoproteins, HDLBiomarkers

Autor:innen und Institutionen

  • Division of Gastroenterology & Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Labcorp, Morrisville, North Carolina, USA.
  • Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
  • Division of Gastroenterology and Hepatology, Virginia Commonwealth University, Richmond, Virginia, USA.

ORCID-Profile: Eduardo Vilar-Gomez, Margery A Connelly, Jill M Rafalko, Arun J Sanyal, Naga P Chalasani, Samer Gawrieh

Förderung

  • NIAAA NIH HHS
  • National Institute on Alcohol Abuse and Alcoholism

Zitieren

APA

Vilar-Gomez, E., Connelly, M. A., Shah, V. H., Shalaurova, I., Rafalko, J. M., Sanyal, A. J., Chalasani, N. P., Gawrieh, S., & TREAT Consortium (2026). Short‐Term Risk Stratification in Alcohol‐Associated Hepatitis: Small HDL Particles and Inflammation Vulnerability Index Values Improve Model for End‐Stage Liver Disease. Alcohol, Clinical and Experimental Research. https://doi.org/10.1111/acer.70388

Vancouver

Vilar-Gomez E, Connelly MA, Shah VH, Shalaurova I, Rafalko JM, Sanyal AJ, et al. Short‐Term Risk Stratification in Alcohol‐Associated Hepatitis: Small HDL Particles and Inflammation Vulnerability Index Values Improve Model for End‐Stage Liver Disease. Alcohol, Clinical and Experimental Research. 2026. doi:10.1111/acer.70388

BibTeX
@article{VilarGomez2026,
  author = {Vilar-Gomez, Eduardo and Connelly, Margery A and Shah, Vijay H and Shalaurova, Irina and Rafalko, Jill M and Sanyal, Arun J and Chalasani, Naga P and Gawrieh, Samer and TREAT Consortium, TREAT Consortium},
  title = {Short‐Term Risk Stratification in Alcohol‐Associated Hepatitis: Small HDL Particles and Inflammation Vulnerability Index Values Improve Model for End‐Stage Liver Disease},
  journal = {Alcohol, Clinical and Experimental Research},
  year = {2026},
  doi = {10.1111/acer.70388}
}
Kostenlos starten →